Last week, our client Breye Therapeutics announced the appointment of Dr Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors. It also launched its new website and LinkedIn page. Breye is a clinical-stage biopharmaceutical company developing novel, oral ophthalmology drugs to address the needs of […]
Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors Funding to advance clinical development of two first-in-class anti-CLDN1 antibodies and the platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies Series C led by Jeito Capital together with Novo Holdings and RA Capital Management Naveed […]
Melanie Senior’s article in Nature Portfolio on ‘Precision Financing’ highlights the rigour behind private biotech financing in 2023 where strong data and efficiency are essential. Two of our clients, Naveed Siddiqi of Novo Holdings and Antoine Papiernik from Sofinnova Partners were featured. Here are some key takeaways… Since the pandemic, the biotech industry has experienced […]
Copenhagen, Denmark – Novo Holdings today announced its financial results for 2022, with a negative -6% return on the Investment Portfolio and Total Income and Returns of DKK 3 billion (€0.4 billion). The positive Total Income and Returns of DKK 3 billion is driven by a strong performance by the Novo Group and resilience in the […]
Aquafortus, a water technology company that purifies high salinity brines and derives valuable metals and minerals from them in the process, today announced the closing of a $17 million oversubscribed Series A1 financing led by DCVC and Novo Holdings, and joined by Universal Materials Incubator, Intrepid Financial Partners, Envisioning Partners, Burnt Island Ventures, K1W1 and […]
